Cargando…

Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists

Background: Mesalazine is among the medications most prescribed by gastroenterologists, with variable and controversial use in different settings. We aimed to explore the use of mesalazine in the clinical practice of young gastroenterologists. Methods: A web-based electronic survey was distributed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Nardone, Olga Maria, Marasco, Giovanni, Lopetuso, Loris Riccardo, Mocci, Giammarco, Pastorelli, Luca, Petruzzellis, Carlo, Scaldaferri, Franco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10004260/
https://www.ncbi.nlm.nih.gov/pubmed/36902792
http://dx.doi.org/10.3390/jcm12052005
_version_ 1784904789291696128
author Nardone, Olga Maria
Marasco, Giovanni
Lopetuso, Loris Riccardo
Mocci, Giammarco
Pastorelli, Luca
Petruzzellis, Carlo
Scaldaferri, Franco
author_facet Nardone, Olga Maria
Marasco, Giovanni
Lopetuso, Loris Riccardo
Mocci, Giammarco
Pastorelli, Luca
Petruzzellis, Carlo
Scaldaferri, Franco
author_sort Nardone, Olga Maria
collection PubMed
description Background: Mesalazine is among the medications most prescribed by gastroenterologists, with variable and controversial use in different settings. We aimed to explore the use of mesalazine in the clinical practice of young gastroenterologists. Methods: A web-based electronic survey was distributed to all participants of the National Meeting of the Italian Young Gastroenterologist and Endoscopist Association. Results: A total of 101 participants took part in the survey, with a majority (54.4%) being aged >30 years, 63.4% of whom were trainees in academic hospitals, and 69.3% of whom were involved in the clinical management of inflammatory bowel disease (IBD). While both non-dedicated and IBD physicians generally agreed on the appropriate dose of mesalazine for mild ulcerative colitis (UC), significant differences were observed between the two groups for moderate-severe ulcerative colitis (UC). Additionally, in IBD patients who were starting immuno-modulators and/or biologics, 80% of IBD-dedicated physicians continued to prescribe mesalazine, compared to 45.2% of non-dedicated physicians (p = 0.002). Indeed, 48.4% of non-dedicated IBD physicians did not acknowledge mesalazine for colorectal cancer chemoprevention. With regards to Crohn’s disease, it is mainly used by 30.1% of IBD physicians for preventing postoperative recurrence of Crohn’s disease. Finally, 57.4% used mesalazine for symptomatic uncomplicated diverticular disease, and 84.2% did not recommend its use for irritable bowel syndrome. Conclusions: This survey showed heterogeneous behaviors in the daily use of mesalazine, mainly in the management of IBD. Educational programs and novel studies are needed to clarify its use.
format Online
Article
Text
id pubmed-10004260
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100042602023-03-11 Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists Nardone, Olga Maria Marasco, Giovanni Lopetuso, Loris Riccardo Mocci, Giammarco Pastorelli, Luca Petruzzellis, Carlo Scaldaferri, Franco J Clin Med Article Background: Mesalazine is among the medications most prescribed by gastroenterologists, with variable and controversial use in different settings. We aimed to explore the use of mesalazine in the clinical practice of young gastroenterologists. Methods: A web-based electronic survey was distributed to all participants of the National Meeting of the Italian Young Gastroenterologist and Endoscopist Association. Results: A total of 101 participants took part in the survey, with a majority (54.4%) being aged >30 years, 63.4% of whom were trainees in academic hospitals, and 69.3% of whom were involved in the clinical management of inflammatory bowel disease (IBD). While both non-dedicated and IBD physicians generally agreed on the appropriate dose of mesalazine for mild ulcerative colitis (UC), significant differences were observed between the two groups for moderate-severe ulcerative colitis (UC). Additionally, in IBD patients who were starting immuno-modulators and/or biologics, 80% of IBD-dedicated physicians continued to prescribe mesalazine, compared to 45.2% of non-dedicated physicians (p = 0.002). Indeed, 48.4% of non-dedicated IBD physicians did not acknowledge mesalazine for colorectal cancer chemoprevention. With regards to Crohn’s disease, it is mainly used by 30.1% of IBD physicians for preventing postoperative recurrence of Crohn’s disease. Finally, 57.4% used mesalazine for symptomatic uncomplicated diverticular disease, and 84.2% did not recommend its use for irritable bowel syndrome. Conclusions: This survey showed heterogeneous behaviors in the daily use of mesalazine, mainly in the management of IBD. Educational programs and novel studies are needed to clarify its use. MDPI 2023-03-02 /pmc/articles/PMC10004260/ /pubmed/36902792 http://dx.doi.org/10.3390/jcm12052005 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nardone, Olga Maria
Marasco, Giovanni
Lopetuso, Loris Riccardo
Mocci, Giammarco
Pastorelli, Luca
Petruzzellis, Carlo
Scaldaferri, Franco
Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists
title Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists
title_full Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists
title_fullStr Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists
title_full_unstemmed Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists
title_short Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists
title_sort insights into mesalazine use in clinical practice of young gastroenterologists
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10004260/
https://www.ncbi.nlm.nih.gov/pubmed/36902792
http://dx.doi.org/10.3390/jcm12052005
work_keys_str_mv AT nardoneolgamaria insightsintomesalazineuseinclinicalpracticeofyounggastroenterologists
AT marascogiovanni insightsintomesalazineuseinclinicalpracticeofyounggastroenterologists
AT lopetusolorisriccardo insightsintomesalazineuseinclinicalpracticeofyounggastroenterologists
AT moccigiammarco insightsintomesalazineuseinclinicalpracticeofyounggastroenterologists
AT pastorelliluca insightsintomesalazineuseinclinicalpracticeofyounggastroenterologists
AT petruzzelliscarlo insightsintomesalazineuseinclinicalpracticeofyounggastroenterologists
AT scaldaferrifranco insightsintomesalazineuseinclinicalpracticeofyounggastroenterologists
AT insightsintomesalazineuseinclinicalpracticeofyounggastroenterologists